# Crossover Study to Evaluate the Abuse Potential of Intranasal Esketamine Compared to Racemic Intravenous Ketamine in Nondependent, Recreational Drug Users

> **NCT02682225** · PHASE1 · COMPLETED · sponsor: **Janssen Research & Development, LLC** · enrollment: 55 (actual)

## Conditions studied

- Drug Abuse

## Interventions

- **DRUG:** Intravenous placebo
- **DRUG:** Intranasal placebo
- **DRUG:** Intravenous racemic ketamine
- **DRUG:** Esketamine 112 mg
- **DRUG:** Esketamine 84 mg

## Key facts

- **NCT ID:** NCT02682225
- **Lead sponsor:** Janssen Research & Development, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-03-25
- **Primary completion:** 2017-01-09
- **Final completion:** 2017-01-09
- **Target enrollment:** 55 (ACTUAL)
- **Last updated:** 2025-04-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02682225

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02682225, "Crossover Study to Evaluate the Abuse Potential of Intranasal Esketamine Compared to Racemic Intravenous Ketamine in Nondependent, Recreational Drug Users". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT02682225. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*